Vaishali Pharma (VAISHALI) Q1 25/26 earnings summary

Executive summary

• Unaudited financial results for the quarter ended June 30, 2025, were approved by the Board on August 11, 2025.

• The Board also approved the Annual Report and Director's Report for FY 2024-25 and the notice for the 18th AGM.

Financial highlights

• Revenue from operations for Q1 FY26 was ₹2,374.71 lakhs, up from ₹1,807.98 lakhs in Q1 FY25.

• Total income for the quarter was ₹2,458.96 lakhs, compared to ₹1,850.44 lakhs in the same quarter last year.

• Profit before tax stood at ₹173.53 lakhs, down from ₹227.02 lakhs year-over-year.

• Net profit for the period was ₹127.93 lakhs, compared to ₹169.90 lakhs in Q1 FY25.

• Basic and diluted EPS for the quarter were ₹0.10, compared to ₹0.15 in the same quarter last year.

Key financial ratios and metrics

• Gross margin impacted by higher expenses, with total expenses rising to ₹2,285.43 lakhs from ₹1,623.41 lakhs year-over-year.

• Employee benefits expense increased to ₹78.43 lakhs from ₹58.68 lakhs year-over-year.